Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LiLa-Bipolar RCT
2023-509607-32-00Phase 4Authorised
- Sponsor
- Frederiksberg Hospital
- Start
- Mar 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in Bipolar II disorder (BP-II) comparing Lithium carbonate with Lamotrigine (Lamictal) (2 arms). Primary endpoint: Mood stabilization (primary). Planned start Mar 2024; status: authorised.
02
Drugs
lithium carbonatelamotrigine
03
Conditions
Bipolar II disorder (BP-II)
Beyond the preview
Go deeper on 2023-509607-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509607-32-00.